

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

AT JANEY'S DOCKET NUMBER

1581/00265

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/830,111

			·	•	09/830,111	
INTERNATIONAL APPLICATION NO.			INTERNATIONAL FIL	ING DATE	PRIORITY DATE CLAIMED	
PCT/JP00/05659			24 August 2000		24 August 1999	
TITI	ÆΟ	F INVENTION				
PROCESS FOR PRODUCING COENZYME Q10						
APPLICANT(S) FOR DO/EO/US MATSUDA, Hideyuki , KAWAMUKAI, Makoto , YAJIMA, Kazuyoshi , IKENAKA, Yasuhiro , Hasegawa, Junzo , TAKAHASHI, Satomi , , , ,						
Applic	ant h	erewith submits to the United States Designate	ed/Elected Office (DO/EO/US)	the following items	and other information:	
 This is a FIRST submission of items concerning a filing under 35 U.S.C. 371 This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. § 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 						
5. □6. □	 a. □ is transmitted herewith (required only if not transmitted by the International Bureau). b. □ has been transmitted by the International Bureau. c. □ is not required, as the application was filed in the United States Receiving Office (RO/US). 					
7. 🗆	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a.					
8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3).						
9. 🗵	9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).					
10. 🗆	0. ☐ A translation of the Annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).				ticle 36	
Items 11. to 16. below concern other document(s) or information included:						
11.		An Information Disclosure Statement under	37 CFR 1.97 and 1.98.			
12.	X	An assignment document for recording. A se	eparate cover sheet in compliance	e with 37 CFR 3.28	and 3.31 is included.	
13. 14.		☐ A SECOND or SUBSEQUENT preliminary amendment.				
15.		A change of power of attorney and/or address	s letter			
16.	X	Other items or information: CRF of Sequence	e Listing and Statement of Ident	ity	•	

07/26/2001 UEDUVIJE 00000031 09830111

01 FC:154

130.00 OP

U.S. APPLICATION NO. (If known, section R 1.5) INTERNATIONAL APPLICATION NO. PCT/JP00/05659				ATTORNEY'S DOCKET NUMBER 1581/00265				
☑ The following f	ees are submitted:	I <u> </u>		CALCU	LATIONS	PTO US	E ONL	Y
Basic National Search Report has been pr International preliminary e	examination fee paid to U	O SPTO (37 CFR 1.482)			\$ - \$ ³			
0.00 No international prelimina search fee paid to USPTO	ry examination fee paid t	o USPTO (37 CFR 1.482	2) but international					
Neither international prelin CFR 1.445(a)(2)) paid to USPTO								
International preliminary e provisions of PCT Article					F	, ,		
	ENTER APPI	ROPRIATE BASIC	FEE AMOUNT =	\$				
Surcharge of \$130.00 for earliest claimed priority da		claration later than 20	□ 30 months from the	\$130				
Claims	Number Filed	Number Extra	Rate			one s		
Total Claims	- 20 =		X \$18.00	\$				
Independent Claims	- 3 =		X \$80.00	\$				
Multiple dependent clain	n(s)(if applicable)		+ \$270.00	\$				
	тот	AL OF ABOVE CA	ALCULATIONS =	\$130				
Reduction by 1/2 for filing	g by small entity, if applie	cable.	,	\$,
			SUBTOTAL =	\$130				
Processing fee of \$130.00 the earliest claimed priorit			20 □ 30 months from	\$				
			ATIONAL FEE =	\$130		ļ		
Fee for recording the enclo by an appropriate cover sh			nt must be accompanied	\$ 40				
		TOTAL FE	ES ENCLOSED =	\$170		ļ		
				Amo	unt to be: refunded			
					charged	\$		
b. Please charge my A duplicate copy c. The Director is he	of this sheet is enclosed.	-0185 in the amount of \$_e any additional fees whic				Deposit A	ccount]	No. <u>22-</u>
NOTE: Where an apprefiled and granted to rest SEND ALL CORR Connolly Bove Lodg 1990 M Street, N.W.	ore the application to p ESPONDENCE T ge & Hutz LLP , Suite 800	ending status O:	Patrick / C	ition to rev	Α	1.137(a)	_	must be
Washington, DC 200	30-3423	0 NAN 24,8						

U.S. Basic National Fee. Copy of the international application.

3. The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

a. Translation of the application into English. A processing fee will be required if submitted later than the appropriate 20 or 30 months from the priority date.

□ The current translation is defective for the reasons indicated on the attached Notice of Defective Translation.
 □ b. Processing fee for providing the translation of the application and/or the Annexes later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(f)).

c. Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), properly identifying the application (preferably by the International application number and international filling date). A surcharge will be required if submitted later than the appropriate 20 or 30 months from the priority date.

The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT/DO/EO/917.

d. Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(e)).

4: Additional claim fees of \$_____ as a ___ large entity ___ small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due (37 CFR 1.492(g)). See attached PTO-875.

5. Applicant has not submitted the required sequence listing pursuant to 37 CFR 1.821-1.825. See attached PCT/DO/EO/920.

ALL OF THE ITEMS SET FORTH IN 3(a)-3(d), 4 AND 5 ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 22 OR 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

6. If box 3a or 3c is checked, a translation of the Annexes MUST be submitted no later than the time period set above or the Annexes will be cancelled. A processing fee will be required if submitted later than 20 or 30 months from the priority date.
7. The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d)) or 30 (37 CFR 1.495(d)) months from the priority date.

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)

	9	A copy of this notice MUST be returned with this response.					
,	Enclosed:	□ PCT/DO/EO/917 □ PTO-875	Notice of Defective T PCT/DO/EO/920	Translation John Anderson	HA		
	FORM PC	T/DO/EO/905 (March 2001)		Telephone: 703-308-9116	-/- '		

Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	•	ATTY, DOCKET NO.		
09/830111	MATSUDA	н	1581/00265		
		INTERNATION	AL APPLICATION NO.		
CONNOLLY BOVE LODGE & HUT 1990 M STREET N W SUITE 800	Z	PCT/JI	200/05659		
WASHINGTON, DC 20036 3425		I.A. FILING DATE	PRIORITY DATE		
		24 AUG 00	24 AUG 99		
			21 MAY 200		
		DATE MAILED:			

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

	The application fails to comply with the requirements of 37 CFR 1.821-1.825.
	This application does not contain, a "Sequence Listing" as a separate part of the
	disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
×	A
	required by 37 CFR 1.821(e).
	A copy of the "Sequence Listing" in computer readable form has been submitted. The
l	content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw
**	Sequence Listing."
	The computer readable form that has been filed with this application has been found to be
	damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
	The paper copy or compact disc of the "Sequence Listing" is not the same as the
1	computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
£	Other:
APPLICA	NT MUST PROVIDE:
×	An initial or substitute computer readable form (CRF) of the "Sequence Listing."
L	An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
×	A state of the contents of the comment disc and the commutar readable form
	are the same and, where applicable, include no new matter, as required by 37 CFR
	1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
•	
CALL:	ESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE
	703) 308-4216, for Rules interpretation,
	703) 308-4212, for CRF submission help,
(703) 287-0200, for PatentIn software help.

John Anderson

Telephone: 703-308-9116

FORM PCT/DO/EO/920 (March 2001)